How have BNOEF shares performed in 2024?

Bionomics' stock was trading at $0.0034 at the beginning of 2024. Since then, BNOEF stock has increased by 0.0% and is now trading at $0.0034. View the best growth stocks for 2024 here .

How do I buy shares of Bionomics?

Shares of BNOEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:BNOEF

Bionomics (BNOEF) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BNOEF Stock Alerts

$0.0034

0.00 (-43.33%)

(As of 09/19/2023)

Compare

Today's Range: $0.0034
▼
$0.0034
50-Day Range: N/A
52-Week Range: $0.00
▼
$0.06

Volume: 22,900 shs
Average Volume: 140,299 shs
Market Capitalization: $4.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Headlines

Get Bionomics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Bionomics Stock (OTCMKTS:BNOEF)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNOEF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BNOEF Stock News Headlines

April 17, 2024 | bbc.co.uk

Chilli beef udon noodles

March 21, 2024 | msn.com

Bionomics to advance non-SSRI PTSD candidate to Phase III

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

January 5, 2024 | tmcnet.com

Bionomics to Present at Biotech Showcase™ 2024

December 30, 2023 | bbc.co.uk

Peter Bone MP loses seat as recall petition triggers by-election

December 6, 2023 | msn.com

Bionomics presents data on reliability of the Subjective Units of Distress Scale

October 16, 2023 | markets.businessinsider.com

Bionomics Secures Buy Rating Amidst Promising BNC210 Developments and Potential Market Entry Advantage

September 29, 2023 | msn.com

Bionomics stock rockets 415% on positive study for PSTD drug

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

September 28, 2023 | proactiveinvestors.com

Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment

September 28, 2023 | marketwatch.com

Bionomics Shares Take Flight on Positive PTSD Study Results

September 28, 2023 | marketwatch.com

Bionomics Shares Rally Premarket on Phase 2B PTSD Study Success

September 28, 2023 | markets.businessinsider.com

Bionomics: Phase 2b ATTUNE Trial With BNC210 Meets Primary Endpoint - Quick Facts

September 28, 2023 | msn.com

Bionomics announces positive results in trial of treatment for PTSD

September 26, 2023 | ftw.usatoday.com

Jay Norvell's beef with Deion Sanders and Colorado is so good for college football

September 14, 2023 | finance.yahoo.com

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

July 9, 2023 | usatoday.com

Mike Trout suffers broken hamate bone, likely out six to eight weeks

April 27, 2023 | finance.yahoo.com

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

March 10, 2023 | markets.businessinsider.com

Positive Report for Bionomics (BNOX) from Evercore ISI

March 8, 2023 | finance.yahoo.com

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

March 3, 2023 | msn.com

Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now

February 10, 2023 | finance.yahoo.com

Bionomics Limited (BNOEF) Stock Historical Prices & Data - Yahoo Finance

December 15, 2022 | marketwatch.com

Bionomics Names Spyridon Papapetropoulos as President, CEO

December 15, 2022 | finance.yahoo.com

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

November 21, 2022 | nz.finance.yahoo.com

Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

November 17, 2022 | marketwatch.com

Bionomics Shares Drop 18% After ADS Offering Prices

October 18, 2022 | seekingalpha.com

Bionomics receives R&D tax incentive refund for FY22 of A$4.6M

See More Headlines

Receive BNOEF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Noncommercial research organizations
Sub-Industry: N/A
Current Symbol: OTCMKTS:BNOEF
CUSIP: N/A
CIK: 1191070
Web: www.bionomics.com.au
Phone: (188) 150-7400
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,309,557,000
Free Float: N/A
Market Cap: $4.45 million
Optionable: Not Optionable
Beta: 1.86

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Adrian Hinton BEC (Age 70)
F.C.A., Financial Controller
Comp: $205.67k
Dr. Spyridon Papapetropoulos M.D. (Age 50)
Ph.D., CEO, Pres & Director
Mr. Timothy M. Cunningham CPA (Age 60)
CPA, M.B.A., Chief Financial Officer
Prof. Paul Rolan D.C.P.S.A.
F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
Dr. Julie Kerner Ph.D.
Sr. VP of Bus. Operations
Dr. Atul R. Mahableshwarkar DFAPA
M.D., Acting Chief Medical Officer
Ms. Suzanne Irwin B.Com.
FCIS, Company Sec.

Key Competitors

View All Competitors

BNOEF Stock Analysis - Frequently Asked Questions

How have BNOEF shares performed in 2024?: Bionomics' stock was trading at $0.0034 at the beginning of 2024. Since then, BNOEF stock has increased by 0.0% and is now trading at $0.0034.
View the best growth stocks for 2024 here.
How do I buy shares of Bionomics?: Shares of BNOEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BNOEF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bionomics (BNOEF) Stock Price, News & Analysis

About Bionomics Stock (OTCMKTS:BNOEF)

BNOEF Stock Price History

BNOEF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BNOEF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info